Efficacy and safety of reduced-dose non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: a meta-analysis of randomized controlled trials

KL Wang, RD Lopes, MR Patel, HR Büller… - European Heart …, 2019 - academic.oup.com
Aims Non-vitamin K antagonist oral anticoagulants (NOACs) require dose reductions
according to patient or clinical factors for patients with atrial fibrillation (AF). In this meta …
被引用次数：51 相关文章

Efficacy and safety of reduced-dose non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: a meta-analysis of randomized controlled trials.

KL Wang, RD Lopes, MR Patel… - European Heart …, 2019 - search.ebscohost.com
Aims Non-vitamin K antagonist oral anticoagulants (NOACs) require dose reductions
according to patient or clinical factors for patients with atrial fibrillation (AF). In this meta …

Efficacy and safety of reduced-dose non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: a meta-analysis of randomized controlled trials

KL Wang, RD Lopes, MR Patel, HR Büller, DS Tan… - 2018 - scholarbank.nus.edu.sg
Efficacy and safety of reduced-dose non-vitamin K antagonist oral anticoagulants in patients
with atrial fibrillation: a meta-analysis of randomized controlled trials | ScholarBank@NUS …
[PDF] researchgate.net

[PDF][PDF] Efficacy and safety of reduced-dose non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: a meta-analysis of randomized controlled …

KL Wang, RD Lopes, MR Patel, HR Buller… - European Heart …, 2019 - researchgate.net
Aims Non-vitamin K antagonist oral anticoagulants (NOACs) require dose reductions
according to patient or clinical factors for patients with atrial fibrillation (AF). In this meta …

Efficacy and safety of reduced-dose non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: a meta-analysis of randomized controlled trials

KL Wang, RD Lopes, MR Patel, HR Büller… - European Heart …, 2019 - academic.oup.com
Aims Non-vitamin K antagonist oral anticoagulants (NOACs) require dose reductions
according to patient or clinical factors for patients with atrial fibrillation (AF). In this meta …

Efficacy and safety of reduced-dose non-vitamin k antagonist oral anticoagulants in patients with atrial fibrillation: A meta-analysis of randomized controlled trials

KL Wang, RD Lopes, MR Patel… - European …, 2019 - researchinformation.amsterdamumc …
Aims Non-vitamin K antagonist oral anticoagulants (NOACs) require dose reductions
according to patient or clinical fac tors for patients with atrial fibrillation (AF). In this meta …

Efficacy and safety of reduced-dose non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: a meta-analysis of randomized controlled trials

KL Wang, RD Lopes, MR Patel… - European heart …, 2019 - pubmed.ncbi.nlm.nih.gov
Aims Non-vitamin K antagonist oral anticoagulants (NOACs) require dose reductions
according to patient or clinical factors for patients with atrial fibrillation (AF). In this meta …

Efficacy and safety of reduced-dose non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: a meta-analysis of randomized controlled trials.

KL Wang, RD Lopes, MR Patel, HR Büller… - European Heart …, 2019 - europepmc.org
Aims Non-vitamin K antagonist oral anticoagulants (NOACs) require dose reductions
according to patient or clinical factors for patients with atrial fibrillation (AF). In this meta …